Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-cash Items (2023 - 2025)

Immunome's Non-cash Items history spans 3 years, with the latest figure at $180.7 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 428.13% year-over-year to $180.7 million; the TTM value through Dec 2025 reached $180.7 million, up 428.13%, while the annual FY2025 figure was $180.7 million, 5243.21% up from the prior year.
  • Non-cash Items reached $180.7 million in Q4 2025 per IMNM's latest filing, up from $87.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $180.7 million in Q4 2025 to a low of $1.6 million in Q2 2023.
  • Average Non-cash Items over 3 years is $52.5 million, with a median of $39.8 million recorded in 2023.
  • The largest YoY upside for Non-cash Items was 3006.85% in 2025 against a maximum downside of 97.56% in 2025.
  • A 3-year view of Non-cash Items shows it stood at $45.4 million in 2023, then fell by 24.58% to $34.2 million in 2024, then soared by 428.13% to $180.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Non-cash Items are $180.7 million (Q4 2025), $87.4 million (Q3 2025), and $62.9 million (Q2 2025).